Evangelos S. Gragoudas, M.D.

Harvard Medical School

Charles Edward Whitten Professor of Ophthalmology, Department of Ophthalmology

Massachusetts Eye and Ear

Distinguished Director, Retina Service
Co-Director, Laser Laboratory
Co-Director, Retina Research Institute
Co-Director, Angiogenesis Laboratory
Senior Scientist

Research Summary

Center/Research Area Affiliations

Research Summary

Dr. Gragoudas played a pivotal role in the development of proton bean therapy (PBT) for uveal melanoma, and performed both preclinical studies and the first clinical studies in patients. He continues to refine PBT and has taken a multidisciplinary approach to developing new strategies for managing uveal melanoma.Studies initiated in the early 1990s with Dr. Joan Miller produced a breakthrough for patients with wetAMD: photodynamictherapy (PDT) with verteporlin (VISudyne®). He and his colleagues identified the important role of vascular endothelial growth factor (VEGF) in ocular neovascularization, which formed the scientific basis for the present antiangiogenic treatments for neovascular AMD and other intraocular vascular diseases.


1965: M.D., Athens National and Capodistrian University, Athens, Greece

Postgraduate Training

1970: Research Fellowship, E.P. Joslin Research, Laboratory Division of Microangiopathy, Harvard Medical School

1972: Residency, Ophthalmology, Boston University Affiliated Hospitals

1973: Chief Resident, Ophthalmology, Boston University Affiliated Hospitals

1974: Clinical Fellowship, Diabetic Retinopathy, Massachusetts Eye and Ear

1975: Fellowship, Retina, Massachusetts Eye and Ear

1976: Research Associate, Eye Research Institute of Retina Foundation, Boston, MA

Academic Appointments

2011-present: Charles Edward Whitten Professor of Ophthalmology, Harvard Medical School

2002-2003: Acting Chairman, Department of Ophthalmology, Harvard Medical School

1994-2011: Professor of Ophthalmology, Harvard Medical School

1981-1994: Associate Professor of Ophthalmology, Harvard Medical School

1978-1981: Assistant Professor of Ophthalmology, Harvard Medical School

1975-1978: Instructor in Ophthalmology, Harvard Medical School


Selected Publications

For a full publication list, please see his CV.

Proton irradiation for peripapillary and parapapillary melanomas. Lane AM, Kim IK, Gragoudas ESArch Ophthalmol. 2011 Sep;129(9):1127-30.

Evaluation of tissue interactions with mechanical elements of a transscleral drug delivery device. Cohen SJ, Chan RVP, Keegan M, Andreoli CM, Borenstein JT, Miller JW, Gragoudas ESPharmaceutics. 2012 Mar 12;4(1):212-229.

High throughput mass spectrometry-based mutation profiling of primary uveal melanoma. Daniels AB, Lee JE, MacConaill LE, Pabescandolo E, Hummelen PV, Adams SM, DeAngelis MM, Hahn WC, Gragoudas ES, Harbour W, Garraway LA, Kim IK. Invest. Ophthalmol. Vis. Sci. 2012 Oct 9;53(11): 6991-6996.

Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families. Njauw CNJ, Kim I, Piris A, Gabree M, Taylor M, Lane AM, DeAngelis MM, Gragoudas E, Duncan LM, Tsao H. PLOS One. 2012;7(4):e35295.

Aminoimidazole carboxamide ribonucleotide (AICAR) inhibits the growth of retinoblastoma in vivo by decreasing angiogenesis and inducing apoptosis. Theodoropoulou S, Brodowska K, Kayama M, Morizane Y, Miller JW, Gragoudas ES, Vavvas DG. PLoS One. 2013;8(1):e52852.

View a complete list of publications on pubmed.gov>>